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Summary We have examined apoptosis and proliferation in lymph node cell suspensions from patients with B-cell non-Hodgkin's lymphoma
using flow cytometry. A method was developed which allowed estimation of the fractions of apoptotic cells and cells in the S-phase of the cell
cycle simultaneously with tumour-characteristic light chain expression. Analysis of the tumour S-phase fraction and the tumour apoptotic
fraction in lymph node cell suspensions from 95 B-cell non-Hodgkin's lymphoma (NHL) patients revealed a non-normal distribution for both
parameters. The median fraction of apoptotic tumour cells was 1.1% (25 percentiles 0.5%, 2.7%). In the same samples, the median fraction
of apoptotic normal cells was higherthan forthe tumour cells (1.9%; 25 percentiles 0.7%, 4.0%; P= 0.03). The median fraction of tumourcells
in S-phase was 1.4% (25 percentiles 0.8%, 4.8%), the median fraction of normal cells in S-phase was significantly lower than for the tumour
cells (1.0%; 25 percentiles 0.6%, 1.9%; P = 0.004). When the number of cases was plotted against the logarithm of the S-phase fraction of
the tumour cells, a distribution with two Gaussian peaks was needed to fit the data. One peak was centred around an S-phase fraction of
0.9%; the other was centred around 7%. These peaks were separated by a valley at approximately 3%, indicating that the S-phase fraction in
NHL can be classified as 'low' (< 3%) or 'high' (> 3%), independent of the median S-phase fraction. The apoptotic fractions were log-normally
distributed. The median apoptotic fraction was higher (1.5%) in the 'high' S-phase group than in the 'low' S-phase group (0.8%; P = 0.02).
However, there was no significant correlation between the two parameters (P > 0.05).
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Carcinogenesis is thought to be driven by the acquisition of
genetic abnormalities in premalignant cells. These genetic changes
lead to a shift in the protein expression pattern, thereby changing
the cellularphenotype. The development ofa dominant clone, as is
seen in most tumours, requires proliferation. Additionally, the rate
ofcell death (by apoptosis) cannot exceed the rate ofproliferation
if there is to be a net increase in tumour mass, which is obviously
the case before treatment is initiated.
The rate of proliferation is difficult to assess directly. Most
investigators have therefore used the fraction ofcells in S-phase as
a measure of proliferative activity, although other methods, e.g.
labelling with the Ki-67 antibody, are also used. A high fraction of
cells in S-phase (or S + G2/M) is correlated with poor prognosis in
B-cell non-Hodgkin's lymphoma (NHL) (Christensson et al, 1989;
Rehn et al, 1990; Macartney et al, 1991; Duque et al, 1993).
Lymphoid cells are eliminated in vivo by apoptosis. A reduced
rate ofapoptosis in neoplastic cells, for example caused by expres-
sion of the bcl-2 protein, would confer a growth advantage on the
tumour cells. The 14;18 translocation seen in follicular centro-
blastic/centrocytic lymphomas (CB/CC) brings the bcl-2 gene
under control of the immunoglobulin heavy chain enhancer, and
may lead to a reduced rate of apoptosis. Indeed, Hollowood and
Macartney (1991) observed a lower apoptotic index in follicular
lymphomas than in reactive germinal centres. Leoncini et al
(1993) assessed the fraction of apoptotic cells in a wide range of
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NHL subtypes. In the 1993 study, apoptotic index was positively
correlated with mitotic index and other measures of growth frac-
tion, and also with increasing histological malignancy grade.
In the reports cited above, S-phase fractions or apoptotic indices
were measured for all cells in the sample, including normal cells,
which are always present in primary tumours. A possible way to
determine the S-phase fraction in the tumour cell population in
mature B-cell neoplasms is to label the cells with fluorescent anti-
bodies against the tumour-characteristic light chain in addition to
the DNA stain (Braylan et al, 1984). This strategy should also be
useful for determining the apoptotic fraction of the tumour cell
population specifically. For assessment of apoptosis by flow
cytometry, free DNA ends in apoptotic cells may be fluorescently
labelled by terminal deoxynucleotidyl transferase (TdT)-mediated
incorporation of tagged nucleotides (Gorczyca et al, 1992, 1993).
We developed a protocol which enabled us to assess simultane-
ously S-phase fraction and apoptotic fraction in both the tumour
cell population and the normal cell population. The results show
that the tumour-specific S-phase and apoptotic fractions are
increased and decreased, respectively, compared with the values
observed fornormal lymphocytes in the same tumoursamples, and
that these parameters are not significantly correlated in B-cell
NHL. The prognostic value of apoptosis and proliferation is
discussed in Stokke et al (1998).
MATERIALS AND METHODS
Patients
Patients included in this study were hospitalized in our institution
during the period 1983-93 and fulfilled the following criteria:
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(1) histopathological diagnosis of NHL according to the modified
Kiel classification (Stansfeld et al, 1988); (2) proofofB-cell origin
of the lymphomas by documentation of light chain restriction of
surface immunoglobulin; and (3) available cell suspensions from
lymph node biopsies stored in liquid nitrogen. Biopsies from 95
patients were measured for apoptosis and proliferation, and clin-
ical data were available for 92 of these. The age range of the 41
women and 51 men was 30-85 years. For 63 patients, the biopsy
was taken at diagnosis, for 15 patients at first and for 14 patients at
second or later relapse/progression. No patients had received
chemotherapy during the last month before the biopsies.
Cells and staining procedures
Single-cell suspensions were prepared as described (Kval0y et al,
1981) from neoplastic lymph nodes frompatients with B-cell NHL
and stored in 10% dimethyl sulphoxide (DMSO) at - 800C.
Thawed samples were washed once in RPMI-1640 medium
(Gibco) with 10% fetal calf serum (FCS), resuspended in phos-
phate-buffered saline (PBS), and fixed for 10 min at 0'C by the
addition of 4% paraformaldehyde to a final concentration of 1%.
After centrifugation, the cell pellets were resuspended in 100%
methanol and stored at - 200C.
Approximately 2 x 106 cells in methanol were washed once in
PBS, resuspended in 50 ,l of TdT solution containing S units of
TdT, 10gl of 5 x reaction buffer, 1.5 mm cobalt chloride (CoCl2)
(the last two supplied with the TdT kit from Boehringer
Mannheim), 0.5 nmol ofbiotin-16-dUTP (Boehringer Mannheim),
0.1 mM dithiothreitol, and incubated at 37'C for 30min. The
controls received no TdT. The cells were washed once in PBS, and
resuspended in fluorescein isothiocyanate (FITC)-streptavidin
(1:50, Amersham) and phycoerythrin (PE)-labelled anti-K oranti-X
antibodies (1:280 or 1:140 respectively, TAGO) in PBS with 0.1%
Triton X-100, and incubated at 0°C for 30 min. The cells were
thereafter washed once in PBS, and resuspended in PBS with
2 jug ml-' Hoechst 33258 in order to stain DNA.
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Flow cytometry
The stained cells were measured in a FACStarPlus flow cytometer
(Becton Dickinson) equipped with two 5-W water-cooled argon
lasers (Spectra Physics) tuned to 488 nm (200 mW) and UV
(100 mW). Pulse digitalization of all signals was triggered on the
forward light scatter signal from the first laser (FSC-H, 488 nm),
the threshold was set at a low level to include apoptotic bodies.
FITC (FL1-H, 520-550 nm) and PE (FL2-H, 560-590 nm) fluo-
rescence as well as forward and side scatter (SSC-H) pulse ampli-
tudes were measured upon excitation by the 488-nm laser. The
overlap of FITC fluorescence into the FL2 channel was compen-
sated for in the hardware. Hoechst 33258 fluorescence pulse
height (F32-H, 400-450 nm), pulse width (F32-W), and pulse area
(F32-A) were measured with UV excitation. The Hoechst 33258
fluorescence pulse area (F32-A) was used as a measure of DNA
content.
Data treatment and statistical analysis
Aggregates of cells were excluded in the F32-W vs. F32-A
cytograms by standard procedures (not shown in the figures). To
reduce the possibility of apoptotic bodies from one apoptotic cell
giving rise to two or more counts, cells with less than half the
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Figure 1 Apoptosis and S-phase in case 358/87. Aggregates were removed by standard procedures before generation of these histograms and cytograms.
(A) shows the cytogram of the tumour-characteristic light chain expression vs DNA content. The light chain expression histogram is shown in (B), with region
'R1' used to generate the DNA histogram (C), and the FITC-dUTP against DNA content cytograms (D) and (E) of the normal cells in the sample. Region 'R2' in
(B) was used to generate the DNA histogram (F), and the FITC-dUTP vs DNA content cytograms (G) and (H) of the tumour cells in the sample. (D) and (G) are
the cytograms for the sample which received TdT, and (E) and (H) are the cytograms for the sample which did not receive TdT (control). Apoptotic cells are
found in region 'R3'
DNA content ofdiploid cells were also gated away. The list-mode
data were further gated on cells which were positive for the
tumour-characteristic light chain (PE fluorescence; regions 'R2' in
Figures 1 and 2), mostly including the lymphoma cells, and on PE-
negative normal cells (regions 'RI' in Figures 1 and 2). The corre-
sponding apoptotic indices were obtained as the fraction of cells
with enhanced FITC fluorescence in the Hoechst 33258 vs. FITC
fluorescence cytograms. The regions defining 'apoptotic' cells
were established from the corresponding control sample (regions
'R3' in Figures 1 and 2) for each lymphoma, and the small fraction
of cells in this region in the control sample (< 0.5%) was
subtracted from the corresponding fraction in the TdT-treated
sample. Apoptotic cells were also gated away before analysing the
cell cycle distribution of the normal and tumour cells using Mod-
Fit software (Verity Software House).
Statistical tests were performed using 'SigmaStat' software
(Jandel Scientific). This software uses the Kolmogorov-Smimov
test to test the normality ofdistributions, using a significance level
ofP = 0.05. Both the S-phase fraction distribution and the apoptotic
fraction distribution failed the normality test, and non-parametric
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tests were used to assess the significance of differences between
populations (Mann-Whitney) or correlation between parameters
(Spearman rank order correlation). The data were also log trans-
formed totest ifthe transformed distribution was normal or showed
other features, e.g. two peaks.
RESULTS
Assessment of the tumour-specific apoptotic and
S-phase fractions
Figure 1 (case 358/87) shows the results obtained with a highly
aneuploid NHL sample. These lymphoma cells also served as tests
to determine iflight chain expression could be used to distinguish
between neoplastic and normal cells in the samples. Figure 1A
depicts the tumour-characteristic light chain expression vs. DNA
content. The PE distribution (Figure iB) shows two populations,
K-negative (normal) cells andK-positive (tumour) cells. Figure IC,
D and E were obtained by gating on the cells which were negative
forlightchain expression (PE-negative, 'RI' in Figure 1B). Figure
IF, G and H were obtained by gating on the cells expressing the
tumour-characteristic light chain (PE-positive, 'R2' in Figure 1B).
The DNA histogram of the PE-negative cells showed mostly
diploid cells, but with some aneuploid cells present (Figure IC).
On the other hand, the DNA histogram of the light chain-
expressing cells revealed mostly aneuploid cells (in this case near-
tetraploid cells; Figure IF). The results for this and eight other
clearly aneuploid tumours (i.e. tumours with two separate peaks in
the ungated DNA histograms, which was the case if the DNA
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Figure 2 Apoptosis and S-phase in case 42/92. Aggregates were removed by standard procedures before generation of these histograms and cytograms. (A)
shows the cytogram of the tumour-characteristic light chain expression vs DNA content. The light chain expression histogram is shown in (B), with region 'Rl'
used to generate the DNA histogram (C), and the FITC-dUTP against DNA content cytograms (D) and (E) of the normal cells in the sample. Region 'R2' in (B)
was used to generate the DNA histogram (F), and the FITC-dUTP vs DNA content cytograms (G) and (H) of the tumour cells in the sample. (D) and (G) are the
cytograms for the sample which received TdT, and (E) and (H) are the cytograms for the sample which did not receive TdT (control). Apoptotic cells are found in
region 'R3'
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Figure 3 Apoptosis and S-phase in non-Hodgkin's lymphoma. The fractions
of tumour cells, i.e. cells expressing the tumour-characteristic light chain, in
S-phase (A) and apoptotic tumour cells (B) were determined as shown in
Figures 1 and 2 and as described in the text. In the dual-parameter plot (C),
low-grade cases (0) and high grade cases (C1) are plotted with different
symbols
index of the tumour was > 1.08) indicated that the gating on light
chain expression efficiently discriminated between the normal and
neoplastic cell populations. The fractions of apoptotic normal and
tumour cells were obtained from Figure 1D and G, respectively,
after having established the regions containing the apoptotic cells
in the control sample which did not receive TdT (Figure 1E and H
respectively; the corresponding light chain and DNA distributions
were equal to the ones shown in Figure IA, B, C and F and are not
shown). A low background of counts in the 'apoptotic' region in
the control sample (< 0.5%) was subtracted from the corre-
sponding fraction obtained for the TdT-stained sample. Case
358/87 had 2.8% apoptotic normal cells and 1.2% apoptotic
tumour cells. Analysis ofthe cell cycle distribution (S-phase frac-
tion) was performed on the DNA histograms shown in Figure IC
and F, except that the apoptotic cells, as defined above, were
excluded. The exclusion of apoptotic cells removed what is
normally considered 'debris' in many of the DNA histograms,
thereby lowering the background counts in the S-phase region.
The resulting background level of S-phase cells was estimated to
be lower than 0.5%. In case 358/87, 2.0% and 1.7% ofthe normal
and tumour cells, respectively, were in S-phase.
Figure 2 shows the near-diploid case 42/92, which had a high
fraction ofboth apoptotic cells (21.5%) and S-phase cells (35.6%) in
the tumour cell population. The normal cell population had a much
lower fraction ofapoptotic cells (4.9%) and S-phase cells (0.8%).
Apoptosis and proliferation in NHL
Ninety-five NHL samples were analysed using the same method
outlined above. The mean coefficients of variation were 3.3%
(s.d. = 0.6%) and 3.4% (s.d. = 0.7%) fortheG, peaks ofthe tumour
cells and normal cells respectively. Table 1 shows the median frac-
tions with lower and upper 25 percentiles ofapoptotic and S-phase
cells for the normal cells and tumour cells in the whole material, as
well as for the high- and low-grade cases and the subgroups of
lymphomas defined by histopathology. The fraction ofapototic and
S-phase normal cells could not be assessed in five and 19 cases,
respectively, because there were too few normal cells in the
samples. The median fraction of apoptotic cells was lower for the
tumour cell populations (1.1%) than forthe normal cell populations
(1.9%; P = 0.03). The median fraction of S-phase cells was higher
for the tumour cell populations (1.4%) than for the normal cell
populations (1.0%; P = 0.004). The median fractions of apoptotic
and S-phase tumour cells were 1.3% and 7.5% respectively for the
high-grade cases. The corresponding median fractions were both
0.9% for the low-grade cases. The difference between the median
fractions of apoptotic tumour cells in high- and low-grade NHL
was not significant (P = 0.58), but the corresponding difference
between the median S-phase fractions was significant (P< 0.0001).
The tumour-specific fractions of apoptotic cells and S-phase
cells were not normally distributed. The log-transformed S-phase
fraction histogram appeared to consist of two peaks (Figure 3A).
We attempted to fit this histogram with one Gaussian peak, but the
residuals were not normally distributed (P = 0.014; P > 0.05 indi-
cates no significant difference from a normal distribution).
However, the data in Figure 3A were fitted well with the sum of
two Gaussian distributions, one centred around 0.9% and the other
around 7% (P = 0.43). This means that B-cell NHL can be classi-
fied as having a 'low' (< 3%), or a 'high' (> 3%) S-phase fraction.
This cut-off is apparently not dependent on the median S-phase
fraction, and is therefore independent ofthe number ofcases with
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'low' and 'high' S-phase fraction. After log transformation, the
distribution of the apoptotic fractions could be fitted with a single
Gaussian peak (Figure 3B; P = 0.35).
The apoptotic fraction was higher in the group of tumours with
high S-phase fraction (median 1.5%) than in the group of tumours
with low S-phase fraction (median 0.8%, P = 0.02). However, the
Spearman rank sum correlation test revealed no significant corre-
lation between S-phase fraction and the apoptotic fraction (Figure
3C; P > 0.05).
DISCUSSION
In view of the possible clinical significance of tumour cell prolif-
eration and apoptosis (Stokke et al, 1998), we developed an assay
which can be used to determine simultaneously the apoptotic frac-
tion and S-phase fraction in the tumour cell population and the
normal cell population in mature B-cell tumours. Apoptotic frac-
tion and S-phase fraction are not necessarily directly proportional
to the rates of apoptosis and proliferation, respectively, but are
expected to be related to these parameters. The assay is based on
the identification of the tumour cell population by the use of fluo-
rescent (yellow-orange) antibodies against the tumour-character-
istic light chain and labelling of the apoptotic cells by
incorporation of a fluorescence-tagged (green) nucleotide
analogue by TdT. Total DNA content is determined by staining
with Hoechst 33258 (blue fluorescence).
The separation of normal and tumour cells based on expression
of the tumour-characteristic light chain is not expected to be
absolute, because normal B-lymphoid cells may also express this.
However, the frequency of cells in a neoplastic lymph node
expressing the opposite of the tumour-characteristic light chain is
very low (Leech et al, 1975; Mann et al, 1976; Levy et al, 1977;
Filippa et al, 1978; Aisenberg et al, 1983), suggesting that the
frequency of normal cells expressing the tumour-characteristic
light chain is also low. Also, our results with aneuploid tumours
(see Figure 1 for a representative case) demonstrate that very few
ofthe normal cells express the tumour-characteristic light chain.
The Tdt reaction, which detects DNA strand breaks, is
commonly used to identify apoptotic cells. However, necrotic cells
also stain weakly with this procedure (an order ofmagnitude lower
than apoptotic cells, unpublished results; Gorczyca et al, 1993).
Hence, the 'apoptosis' region (see Figures 1 and 2) could notbe set
too close to the 'live' cell region, which reduced the sensitivity of
the assay for detecting apoptotic cells. It would be very useful to
be able to identify additionally the necrotic cells. Unfortunately,
with the present fixation conditions, the light scattering cannot be
used to distinguish between cells with intact and damaged
(necrotic) membranes (Stokke et al, 1991). As we use a cut-off in
DNA content (see Materials and methods), we also miss late apop-
totic cells composed ofapoptotic bodies each with a DNA content
below haploid. Counts in the 'apoptosis' region in the control,
which did not receive TdT, also tend to reduce the sensitivity. We
estimated that this effect would set the lower limit for detection of
'apoptotic' cells at approximately 0.5%. On the other hand, the
TdT procedure detects a larger fraction of 'apoptotic' cells and not
just 'apoptotic' bodies, because early apoptotic cells are also
stained. These have activated the endonuclease, but do not display
the classical morphological features of apoptotic cells. As we
employ flow cytometry for the quantitation of apoptosis, there is
virtually no limit to the number of cells that can be analysed.
Hence, small populations of apoptotic cells can be analysed with
the required statistical reliability.
Accurate analysis ofDNA content is required both for the deter-
mination of ploidy and for the reliable estimation of S-phase
fraction. Most investigators have employed propidium iodide for
DNA staining. Our experience is that Hoechst 33258 is superior
for this purpose, as it typically yields considerably lower coeffi-
cients of variation of the GI peak. It was also observed that the
level of what is normally considered 'debris' in the DNA
histograms was reduced or removed by gating away the apoptotic
cells. (Figure 2F is an example ofan ungated DNA histogram with
a large fraction ofapoptotic cells.) For this reason, it is not neces-
sary to use more complex cell cycle models which make certain
assumptions about the 'debris' distribution.
To our knowledge, only one study has been performed where
parameters related to the rate of apoptosis and proliferation have
been assessed in a wide range ofNHL types (Leoncini et al, 1993).
In that study, apoptotic and mitotic figures were counted in
routinely stained sections. Their value for the fraction ofapoptotic
cells was lower (mean < 1%) than ours (mean 2.1% and 3.3% for
tumour and normal cells respectively), which is probably because
we also detected early apoptotic cells with the TdT assay. The S-
phase fractions obtained here are of course much higher than the
mitotic fractions found by Leoncini et al (1993), because S-phase
lasts much longer than mitosis. However, it should be emphasized
thatusing this method (our study) we can assess the apoptotic frac-
tions and S-phase fractions separately for the tumour cells and the
normal cells in the samples. The total (ungated) fractions of apo-
ptotic cells and S-phase cells depend on the fraction of tumour
cells in the sample, and are not necessarily representative foreither
the tumour cells or the normal cells (data not shown). Table 1
shows that the apoptotic fraction in the normal cell population is
often higher than in the tumour cell population (P = 0.03), particu-
larly in the follicular lymphomas (CB/CC), most of which have
14;18 translocations involving the bcl-2 gene and express higher
levels of the bcl-2 protein (unpublished results obtained from the
same tumours as those discussed here).
The results ofLeoncini et al (1993) suggested that apoptosis and
proliferation are co-regulated in NHL, as apoptotic and mitotic
counts were correlated. Our results do not support this conclusion,
as we found no significant correlation between apoptotic fraction
and S-phase fraction for the tumour cells. There may be several
reasons for the discrepancies between the two studies. Different
parameters were measured, although both should be related to
apoptotic rate (the fraction of apoptotic bodies compared with the
fraction of cells with strand breaks), and proliferation rate (the
fraction of mitotic cells compared with the fraction of S-phase
cells). Also, we measured the fraction of apoptotic cells and
S-phase cells in the tumour population only.
In conclusion, our method enables measurement of apoptotic
and S-phase fractions in tumour cells separately from measure-
ment ofthese fractions in normal cells. The apoptotic and S-phase
fractions are reduced and increased, respectively, in lymphoma
cells compared with normal lymphocytes in the same samples.
Also, there is no correlation between these two growth-associated
parameters in NHL.
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